A Multi-institution Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa. Participants will undergo assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period. The study aims to evaluate whether differences in prophylactic therapy are associated with differences in bone health outcomes.
• The participant or legally authorized representative is willing and able to provide written informed consent.
• Diagnosis of severe hemophilia A (factor VIII activity \< 1%).
• Male sex.
• Age between 30 and 50 years (inclusive).
• BMI between 18.5 and 40 kg/m2
• The participant must have been on prophylaxis with Efanesoctocog alfa or Emicizumab for at least 3 months prior to enrollment and intend to remain on the current regimen for the next 5 years.
• Willingness to undergo all research procedures, including DEXA scans and the collection of blood samples.
• Willingness to complete all standard-of-care bleeding and treatment logs.